Bruno Giotti

Bevacizumab and carboplatin-pemetrexed chemotherapy with/out atezolizumab for advanced pleural mesothelioma

Akhil Santhosh, Medical Oncologist at AIIMS Delhi, shared a post on X

“A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab, as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13 18 BEAT-meso trial – Annals of Oncology”

Authors: E. Felip, S. Popat, U. Dafni, K. Ribi, A. Pope, S. Cedres, R. Shah, F. de Marinis, L. Cove Smith, R. Bernabé, M. Früh, K. Nackaerts, L. Greillier, A. Scherz, B. Massuti,  E. Nadal,  L. Vila Martinez, T. Talbot, H. Roschitzki-Voser, G. Dimopoulou,  S. Schär, B. Ruepp, S. Savic, S. Peters, R. Stahel.

Bevacizumab and carboplatin-pemetrexed chemotherapy with/out atezolizumab for advanced pleural mesothelioma

 

A. Pope A. Scherz Akhil Santhosh B. Massuti B. Ruepp cancer E. Felip E. Nadal F. de Marinis G. Dimopoulou H. Roschitzki-Voser K. Nackaerts K. Ribi L. Cove Smith L. Greillier L. Vila Martinez M. Früh OncoDaily Oncology R. Bernabé R. Shah R. Stahel S. Cedres S. Peters S. Popat S. Savic S. Schär T. Talbot U. Dafni